Amivantamab

CHEBI:CHEBI_753136

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2549739
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION
route
INTRAVENOUS
active_ingredient_strength
350 mg/1
marketing_category
BLA
marketing_start_date
20210521
package_marketing_start_date
20210521
labeler_name
Janssen Biotech, Inc.
manufacturer_name
Janssen Biotech, Inc.
generic_name
Amivantamab
brand_name
Rybrevant
brand_name_base
Rybrevant
product_ndc
57894-501
application_number
BLA761210
spl_id
2306e5dc-8308-0b88-e063-6394a90abbc2
active_ingredient_name
AMIVANTAMAB
package_ndc
57894-501-01
package_description
1 VIAL, SINGLE-USE in 1 CARTON (57894-501-01) / 1 INJECTION in 1 VIAL, SINGLE-USE (57894-501-00)
unii
0JSR7Z0NB6
spl_set_id
1466c070-9f97-4fa4-a955-6a6b59981fb8
upc
0357894501015
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class